


## **SARS-CoV-2** Sequencing Update 31 March 2023



Prepared by the National Institute for Communicable Diseases (NICD) of the National Health Laboratory (NHLS) on behalf of the Network for Genomics Surveillance in South Africa (NGS-SA)

Department

Science and Innovation

REPUBLIC OF SOUTH AFRICA


The genomic data presented here are based on South African SARS-CoV-2 sequence data downloaded from GISAID (www.gisaid.org) on 31 March 2023 at 08h43




#### Data license: <a href="https://www.gisaid.org/registration/terms-of-use/">https://www.gisaid.org/registration/terms-of-use/</a>

Elbe, S., and Buckland-Merrett, G. (2017) Data, disease and diplomacy: GISAID's innovative contribution to global health. Global Challenges, 1:33-46. DOI: 10.1002/gch2.1018 PMCID: 31565258

Shu, Y., McCauley, J. (2017) GISAID: Global initiative on sharing all influenza data – from vision to reality. EuroSurveillance, 22(13) DOI: 10.2807/1560-7917.ES.2017.22.13.30494 PMCID: PMC5388101




## GISAID genomes vs total cases, 2020 – 2023 (N=51 126)







#### Number and percentage of clades by epiweek in South Africa, 2022-2023 (17 849\*)



### Detection Rates: Beta, Delta, C.1.2, recombinants, and Omicron




### Prevalence of Variants of Concern (VOC) and Variants of Interest (VOI) in



Note: XBF is an Omicron-Omicron recombinant and so is counted in the total number of Omicrons.

## South Africa, 2022-2023, n = 17 849\*




Surveillance in South Africa

\*Recombinants include all recombinant lineages (viruses consisting of segments of two different lineages) detected in South Africa at low levels. Currently it consists of XT, XAS, XAZ, XBA, XBF.

## Eastern Cape Province, 2022-2023, n = 930


Genomes added since last report: 8\*



Surveillance in South Africa

## Free State Province, 2022-2023, n = 569


Genomes added since last report: 2\*



Surveillance in South Africa

## Gauteng Province, 2022-2023, n = 5126


Genomes added since last report: 125\*



Surveillance in South Africa


## KwaZulu-Natal Province, 2022-2023, n = 2007

Genomes added since last report: 11\*




## Limpopo Province, 2022-2023, n = 917

Genomes added since last report: 1\*




## Mpumalanga Province, 2022-2023, n = 1422

Genomes added since last report: 5\*




## **Northern Cape Province**, 2022-2023, n = 582

Genomes added since last report: 18\*




## North West Province, 2022-2023, n = 657

Genomes added since last report: 9\*



## Western Cape Province, 2022-2023, n = 5632

Genomes added since last report: 214\*



## Summary


- Sequencing update
  - All provinces have sequences for January and February 2023. March sequences are from the Eastern Cape, Free State, Gauteng, KwaZulu-Natal, the North West, and the Western Cape.

#### • Variant of Concern Omicron in South Africa

- Omicron continued to dominate in January (99%), February (100%) and makes up 100% of March sequences
- BQ.1 and sub-lineages were the dominant Omicron lineage in December (46%) and January (53%)
- XBB.1.5 was detected in December 2022 (0.8%) and January 2023 (16%), and is the dominant lineage in February (71%) and March (76%)
- BA.2.75.\* continued to be detected at a low prevalence in January through March (≤1%)



Spike protein mutation\* profile of Variants of Interest and Concern



- Multiple changes within the two immunogenic regions in S1 (NTD and RBD)
  - Including a three amino acid insertion
- Accumulation of mutations surrounding the furin cleavage site
  - Including combination of N679K and P681H
- Effect of most spike S2 subunit changes have not been defined, but may be linked to immune escape


\*Only mutations present in Omicron, Delta, or recombinant sequences are pictured



## BQ.1\* and XBB.1.5\* spike mutations\*

Frequency of spike SNVs for Omicron (22E/BQ.1.\*) (n = 1094)

NTD RBD RBM S1 S2 HR1



Mutation

#### **University of Stellenbosch** & NHLS Tygerberg Virology



Susan Engelbrecht Wolfgang Preiser Gert van Zyl Tongai Maponga **Bronwyn Kleinhans** Shannon Wilson Karabo Phadu Tania Stander Kamela Mahlakwane Mathilda Claassen **Diagnostic laboratory staff** 

#### **UKZN-Inkosi Albert Luthuli Central Hospital**



Dr Khanyi Msomi Dr Neli Ngcaba Dr Kerusha Govender Dr Tshepiso Mosito Dr Pravi Moodlev Mr Malcolm Ellapen Dr Aabida Khan Mr Kubendran Reddy Dr Lili Gounder The COVID-19 Bench team Dr Kerri Francois Dr Cherise Naicker Dr Joedene Chetty

#### University of KwaZulu-Natal & Africa **Health Research Institute**



Tulio de Oliveira Richard Lessels Houriivah Tegally Eduan Wilkinson Jennifer Giandhari Sureshnee Pillav **Emmanuel James San** 

KRISP at UKZN:

AHRI **AHRT**AFRICA RESEARCH INSTITUTE Alex Sigal Sandile Cele Willem Hanekom

#### National Institute for Communicable Diseases



Diseases & Meningitis Anne von Gottberg Thabo Mohale Daniel Amoako Josie Everatt Boitshoko Mahlangu Noxolo Ntuli Anele Mnguni Amelia Buys Cardia Fourie Noluthando Duma Linda de Gouveia Jackie Kleynhans Nicole Wolter

Mignon du Plessis Stefano Tempia Mvuyo Makhasi Cheryl Cohen



Centre for HIV and STIs Sequencing Core Facility Zamantungwa Khumalo Cathrine Scheepers Annie Chan **Constantinos Kurt Wibmer** Morne du Plessis Stanford Kwenda Phillip Senzo Mtshali Mushal Allam Florah Mnvameni Arshad Ismail

Samrc





#### University of the **Free State**



#### UFS

**Dominique Goedhals** Armand Bester Martin Myaga Peter Mwangi **Emmanuel Ogunbavo** Milton Mogotsi Makgotso Maotoana Lutfiyya Mohamed



NHLS Division of Virology Sabeehah Vawda Felicity Burt Thokozani Mkhize **Diagnostic laboratory staff** 



#### University of Cape Town, NHLS & Western Cape Government



Annabel Enoch This project has eceived funding from



#### UCT. IDM and CIDRI-Africa

Deelan Doolabh Arash Iranzadeh Lynn Tyers Innocent Mudau Nokuzola Mbhele Fezokuhle Khumalo Thabang Serakge Sean Wasserman Bruna Galvão Linda Boloko Arghavan Alisoltani (U. California)

the European Union's Horizon Europe Research and Innovation Actions under grant No 101046041



CAPE TOWN HVTN

cience & innovation

Zoonotic arbo and respiratory virus program **Centre for Viral Zoonoses Department Medical Virology/ NHLS Tshwane Academic division University of Pretoria** 

> ZARV research program/UP Marietjie Venter (Head: ZARV) Adriano Mendes (Postdoc) Amy Strydom (Postdoc) Michaela Davis (MSc, intern medical scientist) Carien van Niekerk

NHLS Tshwane Prof Simnikiwe Mayaphi (HOD)

#### Funders:

8

GIZ/BMBF: African Network for Improved diagnostics and epidemiology of common and emerging infectious agents (ANDEMIA) G7 Global Health fund, Robert Koch Institute, Dr Fabian Leendertz

**Centre for Respiratory Jinal Bhiman** Frances Ayres Penny Moore

Sibongile Walaza



Thandeka Movo **Tandile Hermanus** Zanele Molaudzi Bronwen Lambson











NICD COVID-19 response team NICD SARS-CoV-2 Sequencing Group

AFRICA CDC

**Tandile Hermanus** Mashudu Madzivhandila Prudence Kgagudi **Brent Oosthuysen** 



## 

Key to Diagnostic Excellence

AMPATH

LABORATORIES

ir---i

PathCare

Vermaak

africa

aboratorie

FIOCRUZ



**Hyrax Biosciences** Simon Travers

**Cape Town HVTN Laboratory** Erica Anderson-Nissen Anneta Naidoo

**Ndlovu Research** Hugo Tempelman CJ Umunnakwe

#### **Lancet** Allison J. Glass Raquel Viana

Ampath Terry Marshall Cindy van Deventer Eddie Silberbauer

Pathcare Vermaak Andries Dreyer Howard Newman Riaan Writes Marianne Wolfaardt Warren Lowman

Bridge-the-Gap Raymond Rott

**Cytespace Africa Laboratories** Christa Viljoen

ARC-OVI Lia Rotherham **CAPRISA** Salim Abdool Karim Nigel Garret

**Additional support and collaborators** 

UKZN - Big Data Francesco Pettruccione Ilya Sinayskiy

University of Oxford José Lourenço

FioCruz, Brazil Vagner Fonseca Marta Giovanetti Luiz Carlos Junior Alcantara Africa CDC and Africa PGI John Nkengasong Sofonias Tessema

Netcare Richard Friedland Craig Murphy Caroline Maslo Liza Sitharam

#### DSI

Glaudina Loots

**SA MRC** Glenda Gray

Pathcare N1 City Jean Maritz Nadine Cronje Petra Raimond Kim Hoek
























**NATIONAL HEALTH** LABORATORY SERVICE

## South African genomes submitted per submitting lab, 2020 - 2022 (N=51 126)

Submitting labs in South Africa



#### **NGS-SA Labs**

**CERI**: Centre for Epidemic Response and Innovation **KRISP:** KZN Research Innovation and Sequencing Platform NDLOVU: Ndlovu Research Laboratories **NICD**: National Institute for Communicable Diseases **NHLS**: National Health Laboratory Service **SU**: Stellenbosch University **UCT**: University of Cape Town **UFS**: University of the Free State **UP**: University of Pretoria

Multiple labs from NGS-SA and collaborating public and private laboratories are contributing to sequencing, both as originating and as submitting (pictured here) laboratories.



## Currently circulating Variants of Interest (VOI) as of 15 March 2023

Pango lineage∙	Nextstrain clade	Genetic features	Earliest documented samples	Date of designation	
XBB.1.5	23A	Recombinant of BA.2.10.1 and BA.2.75 sublineages, i.e. BJ1 and BM.1.1.1, with a breakpoint in S1.	05-01-2022	11-Jan-2023	
		XBB + S:F486P			

https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ accessed 17 March 2023

## **Omicron subvariants under monitoring**

Pango lineage <sup>#</sup> (+ mutation)	GISAID clade	Nextstrain clade	Relationship to circulating VOC lineages	Spike genetic features	Earliest documented samples
BQ.1 <sup>\$</sup>	GRA	22E	BA.5 sublineage	BQ.1 and BQ.1.1: BA.5 + S:R346T, S:K444T, S:N460K	07-02-2022
BA.2.75 <sup>§</sup>	GRA	22D	BA.2 sublineage	BA.2.75: BA.2 + S:K147E, S:W152R, S:F157L, S:I210V, S:G257S, S:D339H, S:G446S, S:N460K, S:Q493R reversion	31-12-2021
CH.1.1 <sup>§</sup>	GRA	22D	BA.2 sublineage	BA.2.75 + S:L452R, S:F486S	27-07-2022
XBB <sup>µ</sup>	GRA	22F	Recombinant of BA.2.10.1 and BA.2.75 sublineages, i.e. BJ1 and BM.1.1.1, with a breakpoint in S1	BA.2+ S:V83A, S:Y144-, S:H146Q, S:Q183E, S:V213E, S:G252V, S:G339H, S:R346T, S:L368I, S:V445P, S:G446S, S:N460K, S:F486S, S:F490S	13-08-2022
XBF	GRA		Recombinant of BA.5.2.3 and CJ.1 (BA.2.75.3 sublineage)	BA.5 + S:K147E, S:W152R, S:F157L, S:I210V, S:G257S, S:G339H, S:R346T, S:G446S, S:N460K, S:F486P, S:F490S	27-07-2022

# includes descendent lineages

\$ additional mutation outside the spike protein: ORF1a: Q556K, L3829F, ORF1b: Y264H, M1156I, N1191S, N: E136D, ORF9b: P10F § additional mutations outside of the spike protein: ORF1a: S1221L, P1640S, N4060S, ORF1b: G662S, E: T11A µ additional mutations outside of the spike protein: ORF1a: K47R, ORF1b: G662S, S959P, E: T11A, ORF8: G8\*

## Submission of routine specimens for sequencing

- representative of multiple geographic regions (provinces/districts/health facilities) from individuals of
  - all ages
  - over as many time periods during the SARS-CoV-2 epidemic in South Africa
- requested that testing laboratories in both the private and public sectors, submit respiratory samples to their closest NGS-SA sequencing laboratory on a routine basis (ideally every week) as follows, depending on the capacity of the testing laboratory:
  - All positives samples should be sent every week (NGS-SA laboratory will perform random sampling as described below) OR
  - A weekly selection of approximately 10%-20% of randomly selected positive samples should be sent every week. Number of selected samples will depend on the size of laboratory and how many other laboratories are drained by the submitting laboratory.

# Submission of special interest specimens for sequencing

In addition to routine samples mentioned above, please send specimens separately to above and clearly marked if:

- Suspected vaccine breakthrough (≥14 days after vaccine), especially if hospitalised and clinically severe
- Suspected re-infection (≥90 days after previous episode), especially if hospitalised and clinically severe
- Prolonged shedding with high SARS-CoV-2 viral loads (i.e. Ct values less than 30 for more than 1 month post-primary diagnosis) in immunocompromised individuals
- Possible animal-to-human transmission
- Suspected cases of importation from another country, especially countries known to harbour SARS-CoV-2 variants of concern or countries with little available information
- Clusters of "unusual" cases (e.g., in terms of disease presentation, patient groups affected, etc.)